Depo Provera Lawsuit [September 2025 Update] | File A Claim

August 25, 2025: Depo-Provera Lawsuits Surpass 960 Filings With Over 9,500 Claims Under Review

Nearly 1,000 Depo-Provera meningioma lawsuits are now pending nationwide, while more than 9,500 additional claims are still under investigation. 

The lawsuits allege that long-term use of Depo-Provera, a hormonal contraceptive injection, increased the risk of meningioma, a brain tumor that can lead to neurological impairment, headaches, and vision loss.

Earlier this year, the Judicial Panel on Multidistrict Litigation (JPML) consolidated Depo-Provera lawsuits into multidistrict litigation (MDL) before U.S. District Judge M. Casey Rodgers in the Northern District of Florida. Multidistrict litigation streamlines pretrial proceedings by centralizing federal claims with common issues, allowing coordinated discovery and early test trials.

Pfizer, the manufacturer of Depo-Provera, is expected to file a motion for summary judgment this month, arguing that federal law preempts the claims.

If the litigation proceeds past the preemption challenge, five bellwether cases will be prepared for early jury trials. 

Bellwether trials provide insight into how juries may respond to evidence and testimony, and the results often shape broader settlement negotiations.

Depo-Provera contains medroxyprogesterone acetate, a synthetic progestin administered every three months as birth control.

The lawsuits reference recent research indicating that women who used Depo-Provera for more than one year faced a more than fivefold increased risk of developing meningioma.

Plaintiffs allege that Pfizer failed to adequately warn about these risks and prioritized sales over patient safety.

August 18th, 2025: Ohio Woman Files Lawsuit After Brain Tumor Allegedly Linked to Depo-Provera Use

An Ohio woman has filed a lawsuit against Pfizer and other manufacturers of Depo-Provera, alleging the birth control shot caused her to develop a debilitating brain tumor requiring lifelong medical monitoring.

The plaintiff began using Depo-Provera in 1994 and received the injections for 10 years.

She was diagnosed with an intracranial meningioma in 2023 after experiencing symptoms such as seizures, balance problems, and persistent headaches.

The lawsuit claims that the manufacturers failed to adequately warn about the risk of brain tumors linked to depot medroxyprogesterone acetate (DMPA), the active ingredient in Depo-Provera.

Shepherd underwent surgery to remove the tumor, but now requires routine MRIs and CT scans to monitor for recurrence and faces long-term psychological distress due to the risk of future neurological damage.

Filed in the Northern District of Florida, Shepherd’s case is part of the growing Depo-Provera brain tumor litigation now consolidated under U.S. District Judge M. Casey Rodgers.

Early “pilot” trials are being prepared to test the strength of the claims before juries.

Plaintiffs argue that the drug’s manufacturers ignored data linking DMPA use to intracranial meningiomas and failed to update warnings despite mounting evidence.

August 5th, 2025: Depo-Provera Brain Tumor Lawsuit Update

A new Depo-Provera lawsuit filed by a Louisiana woman alleges she developed an intracranial meningioma after receiving Depo-Provera injections from 2001 to 2012.

Her symptoms escalated to include full-body numbness on the left side, culminating in invasive brain surgery in 2019

The Plaintiffs case joins over 550 others now centralized in a multidistrict litigation (MDL) before Judge M. Casey Rodgers in the Northern District of Florida.

The lawsuits accuse Pfizer and its affiliated companies of failing to warn patients and doctors about the risks of intracranial meningiomas tied to prolonged exposure to medroxyprogesterone.

Medroxprogesterone is the active ingredient found in the Depo-Provera shot.

Scientific studies have indicated that synthetic progestins like those in Depo-Provera may contribute to tumor growth.

Plaintiffs argue that these dangers were known or should have been known long before recent research brought them to light.

Bellwether trials are now being prepared to assess jury reactions to the core evidence and expert testimony.

These early trials will help shape the future of potential settlements or continued litigation for thousands of women affected.

August 1, 2025: August 2025 JPML Update

The Depo-Provera MDL grew by 115 cases between July and August, bringing the total to 550.

Plaintiffs continue to allege that Pfizer’s injectable contraceptive caused them to suffer serious bone density loss.

The increase reflects steady plaintiff-side activity as more individuals come forward with long-term health concerns tied to the product.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly. 

July 29th, 2025: Judge Demands Transparency on Unified Depo-Provera Meningioma Lawsuits

The federal judge overseeing the growing number of Depo-Provera brain tumor lawsuits is pressuring plaintiffs’ lawyers to disclose how many cases remain unfiled.

Judge M. Casey Rodgers, who presides over the MDL in the Northern District of Florida, raised concerns that attorneys are delaying the filing of claims until the court rules on key preemption defenses later this year.

As of now, more than 550 lawsuits have been filed by women who developed meningiomas after receiving Depo-Provera, a long-acting birth control injection manufactured by Pfizer and generic drugmakers.

However, plaintiffs have indicated that hundreds (or potentially thousands) more cases are likely to be filed.

The lawsuits claim that Depo-Provera increases the risk of intracranial meningiomas, citing recent studies showing a five-fold increased risk in certain users.

Plaintiffs argue that the drug manufacturers failed to warn women and healthcare providers of this danger.

Judge Rodgers warned that delaying the filing of cases until after a decision on Pfizer’s preemption defense (which argues that federal law barred it from changing the warning label) is disruptive to the litigation process.

She made clear that leadership roles in the MDL could be revoked if firms wait to file en masse after the ruling.

The deadline to certify the number of unfiled claims is July 31, and oral arguments on preemption are scheduled for September 29.

If the claims survive, five bellwether trials will move forward, offering key insights into jury response and influencing possible settlement talks.

July 22, 2025: Depo-Provera Lawsuit Filed Over Meningioma Diagnosis and Brain Surgery After Long-Term Use

A Nebraska woman has filed a product liability lawsuit against Pfizer Inc., alleging that her long-term use of the injectable contraceptive Depo-Provera caused her to develop multiple meningiomas, requiring invasive brain surgeries.

The lawsuit, filed on July 16, 2025, in the U.S. District Court for the Northern District of Florida, joins a growing multidistrict litigation (MDL No. 3140) involving over 500 similar claims.

The plaintiff, Amy Samsel, used Depo-Provera for more than 21 years before being diagnosed with two brain tumors in 2023.

According to the complaint, the tumors led to neurological symptoms including dizziness, vision problems, and papilledema. She underwent two craniotomies to remove the tumors.

Samsel alleges that Pfizer and other defendants failed to warn about the known risk of intracranial meningiomas associated with long-term use of Depo-Provera.

The suit cites scientific research dating back to the 1980s, including a 2024 French study linking prolonged progestin use with a 5.6-fold increased risk of meningioma.

While European and Canadian regulators have added meningioma warnings to Depo-Provera labeling, similar disclosures have not been implemented in the U.S.

Claims in the lawsuit include failure to warn, design defect, negligence, misrepresentation, and breach of warranty.

The case is part of coordinated pretrial proceedings overseen by Judge M. Casey Rodgers, who has scheduled a series of bellwether trials to begin in the coming year.

The outcome of early trial cases may influence the direction of future settlements or rulings in the MDL.

July 16, 2025: Over 550 Depo-Provera Lawsuits Consolidated in MDL Over Brain Tumor Allegations

More than 550 product liability lawsuits have been filed against Pfizer over allegations that its contraceptive injection, Depo-Provera, caused users to develop meningioma brain tumors.

Depo-Provera Lawsuits have been consolidated in federal multidistrict litigation (MDL No. 3140) in the U.S. District Court for the Northern District of Florida under Judge M. Casey Rodgers.

Countless plaintiffs allege they developed serious brain tumors after receiving Depo-Provera injections over extended periods.

Discovery is currently underway, and early bellwether trial selections are expected in late 2025 or early 2026.

Pfizer is expected to challenge the claims through preemption defenses, asserting that federal regulatory approval of Depo-Provera bars state-level failure-to-warn claims. Briefing on these motions is anticipated later this year.

Depo-Provera packaging in the U.S. does not currently include a warning about meningioma risks.

In contrast, regulators in Europe and Canada require such warnings.

Plaintiffs in the MDL generally allege that Pfizer knew or should have known about the risk and failed to adequately inform users and the medical community.

The lawsuits seek compensation for medical expenses, lost wages, and long-term disability associated with brain tumor treatment.

TorHoerman Law is currently reviewing potential claims involving individuals who developed meningioma after receiving Depo-Provera injections.

July 14, 2025: Judge Orders Disclosure of Pre-Settlement Loans in Depo-Provera Lawsuits

On July 9, 2025, U.S. District Judge M. Casey Rodgers issued a pretrial order requiring all plaintiffs involved in the Depo-Provera multidistrict litigation (MDL) to disclose details of any pre-settlement funding arrangements.

The order mandates attorneys to submit documentation identifying the funding company, loan amount, interest rate, fees, and repayment terms.

The court expressed concern that some plaintiffs may have entered into high-interest funding agreements that could influence their settlement decisions.

Judge Rodgers emphasized the need to protect plaintiffs from predatory lending practices that may erode their financial recovery and interfere with the resolution of the litigation.

The disclosure order follows a broader judicial trend of increasing transparency around third-party litigation financing, particularly in mass tort cases where plaintiffs may face financial hardship while awaiting trial or settlement.

The Depo-Provera MDL consolidates claims alleging that the injectable birth control caused irreversible bone density loss and other long-term health effects.

Pretrial proceedings continue as parties engage in coordinated discovery and settlement discussions.

July 3rd, 2025: Depo-Provera Lawsuits Allege Brain Tumor Risks from Long-Term Use

Pfizer is currently facing a growing wave of litigation in both the U.S. and U.K. from hundreds of women who claim that long-term use of Depo-Provera caused them to develop meningiomas—noncancerous but potentially dangerous brain tumors.

The lawsuits were filed following a 2024 British Medical Journal study that linked progestogens, the hormone used in Depo-Provera, to a significantly increased risk of meningiomas.

The study found that women using the injection for over a year had a 5.6 times greater likelihood of developing the tumors.

A separate 2024 study published by the National Library of Medicine supported these findings.

Despite these emerging concerns, Depo-Provera’s official U.S. label still does not mention meningioma risks as of mid-2025.

Plaintiffs allege Pfizer was aware of these dangers but failed to warn consumers or update safety information in the U.S., even though similar warnings were issued in other countries.

Depo-Provera is approved to prevent pregnancy for three months per injection and is not recommended for use beyond two years.

Plaintiffs argue that Pfizer failed to communicate safer alternatives or adequately update risk disclosures, potentially exposing millions of women to long-term harm.

July 1st, 2025: July 2025 JPML Update

The Depo-Provera MDL rose to 435 cases by July 1st, up from 348 in June.

This is the largest monthly increase reported since tracking began.

Plaintiffs allege that the birth control injection caused bone density loss and other long-term health complications.

The litigation is still in early procedural stages, with coordination focused on consolidating claims and case management.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly.

June 16th, 2025: Generic Defendants Likely to Be Dismissed as Brand Cases Advance

On June 11, U.S. District Judge M. Casey Rodgers, who is presiding over the federal multidistrict litigation (MDL) regarding Depo-Provera birth control shots, issued a case management order.

This order suggests that the authorized generic manufacturers Greenstone, Viatris, and Prasco will likely be excluded from the litigation soon.

During a case management conference on May 30, plaintiffs’ attorneys suggested that these companies are expected to be released, awaiting further assessment of their role related to the drug.

The MDL now encompasses over 400 Depo-Provera Lawsuits, centering on claims that these birth control injections contributed to the development of meningioma brain tumors, with Pfizer and other brand-name manufacturers purportedly failing to disclose this risk.

Since March 2025, over 300 lawsuits have been consolidated.

Discovery is ongoing, as the deadlines for producing documents related to preemption and general causation have passed since May 11.

Judge Rodgers stated that bellwether trials are slated to begin in late 2026 or early 2027 to assess key arguments and support possible settlements.

June 12, 2025: Pfizer Seeks Dismissal of Depo-Provera Brain Tumor Lawsuits on Preemption Grounds

On September 29, 2025, U.S. District Judge M. Casey Rodgers will hear oral arguments on Pfizer’s motion to dismiss over 400 lawsuits filed in the Depo-Provera brain tumor multidistrict litigation.

The motion centers on federal preemption, a legal doctrine that could block the cases from proceeding to discovery.

Pfizer argues that it cannot be sued under state failure-to-warn laws because the U.S. Food and Drug Administration previously rejected a proposed warning about brain tumor risks for Depo-Provera.

The company contends that federal law preempts any state law claims requiring a warning the FDA declined to approve.

Plaintiffs argue that Pfizer has not met the high burden required to invoke preemption and maintain that the FDA’s denial did not amount to a categorical prohibition on additional warnings.

They assert that drug manufacturers can still be held liable under state law when new evidence of risk emerges. Plaintiffs cite recent studies linking Depo-Provera to increased risks of brain tumors as justification for their claims.

The court’s decision could determine whether the federal litigation moves forward into discovery or is dismissed at the threshold. A ruling is expected in October.

June 5th, 2025: Pfizer Advocates for Mass Tort Program in Pennsylvania Depo-Provera Litigation

Pfizer has requested that the Philadelphia Court of Common Pleas establish a mass tort program for lawsuits concerning Depo-Provera brain tumors.

Although only two lawsuits have been filed in Philadelphia so far, one involves over 100 plaintiffs.

Nearly all the plaintiffs had their claims severed and dismissed without prejudice on May 30, allowing them to refile individually.

Pfizer expects a surge in new filings and argues that centralizing the cases will streamline the litigation process.

Attorneys anticipate that the court’s decision on whether to approve the mass tort program could greatly affect how the Pennsylvania docket proceeds.

TorHoerman Law associate attorney Alexis Robinson has provided an update on the progress of the Depo-Provera Lawsuits.

Judge Casey Rogers has been assigned to oversee the litigation and has set regular status conferences through 2025 to keep the case on track.

She recently issued an order to show cause against the manufacturers, Greenstone and Biatric, for missing court-imposed deadlines.

In addition, she selected five early cases to proceed as bellwether trials, a significant step that can help determine how the larger pool of cases may be resolved.

Judge Rogers has also implemented a streamlined process for obtaining medical records and issuing subpoenas to medical providers and pharmacies.

Her prior experience managing large-scale mass torts is expected to support an efficient and organized path forward in the Depo-Provera Lawsuit proceedings.

Her active management may help accelerate progress toward resolution.

The court’s increasing activity makes it important for potential claimants to act quickly, as the time to join the litigation may be limited.

Individuals who believe they may qualify should start the process by completing the online chat feature evaluation on our website.

Current clients should ensure they complete the onboarding process in full to avoid missing deadlines that could impact their claims.

As with all complex litigation, timelines and procedures may shift as the case evolves.

The information provided here reflects current expectations and should be viewed as a general update rather than a guarantee of outcome or timing.

June 2nd, 2025: June 2025 JPML Update

The Depo-Provera MDL grew by an additional 59 new cases between May and June, bringing the total to 348.

Lawyers are reviewing medical histories and expert reports as preliminary discovery efforts begin to shape the core claims in the litigation.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly. 

May 27, 2025: Lower-Dose Depo-SubQ Provera 104 Could Factor Heavily in Brain Tumor Lawsuits

As litigation over alleged brain tumor risks tied to Depo-Provera continues to grow, attention is turning to a lower-dose alternative that some experts say may have posed fewer risks to long-term users.

Depo Sub-Q Provera 104, a formulation developed by Pfizer, delivers 104 mg of medroxyprogesterone acetate via subcutaneous injection.

That’s significantly less than the 150 mg dose delivered intramuscularly in the traditional Depo-Provera shot.

Medical experts suggest the lower dose could have substantially reduced the risk of meningioma, which are non-cancerous brain tumors linked to long-term use of synthetic hormones.

They believe this is because a lower dose would lead to less hormone buildup in the body over time.

Despite this potential safety benefit, Pfizer made limited efforts to transition patients to the lower-dose version, according to attorneys representing plaintiffs in the Depo-Provera multidistrict litigation (MDL).

Lawyers argue the decision to continue promoting the higher-dose product was driven more by market considerations than medical ones.

May 19th, 2025: New Study Links Long-Term Depo-Provera Use to Tripled Risk of Brain Tumors, Fueling MDL Claims Against Pfizer

A new peer-reviewed study published in February 2025 has added significant weight to the growing body of evidence linking Depo-Provera to brain tumors.

Researchers from the University of British Columbia conducted a large-scale nested case-control study comparing users of Depo-Provera to users of a common oral contraceptive (ethinylestradiol-levonorgestrel).

Their analysis, based on U.S. insurance claims data, found that women who used Depo-Provera for more than one year were 3.5 times more likely to develop meningioma than those on oral contraceptives.

The researchers used rigorous methods to account for disease latency and other confounding factors, addressing concerns raised by earlier studies that lacked active comparators or control for the timing of tumor development.

Notably, the risk remained elevated even after longer use, with adjusted incidence rate ratios of 2.95, 3.17, and 3.50 for two, three, and four years of use, respectively.

The study underscores a possible biological mechanism for the risk, as meningiomas frequently overexpress progesterone receptors—the same receptors targeted by Depo-Provera to prevent pregnancy.

Although the European Medicines Agency has recommended adding meningioma warnings to Depo-Provera’s label, the U.S. FDA has not yet followed suit.

Plaintiffs in the Depo-Provera multidistrict litigation (MDL) have cited emerging studies like this one to argue that Pfizer failed to adequately warn women about long-term tumor risks.

With over a million prescriptions filled annually, the findings are expected to play a key role in both ongoing discovery and potential bellwether trials in the Depo-Provera brain tumor MDL.

May 1st, 2025: May 2025 JPML Update

159 cases have been added to the Depo-Provera MDL in the past month, the largest influx of cases since the MDL was established.

As more individuals become aware of the links between Depo-Provera and brain tumors, the number of lawsuits continues to increase.

The federal lawsuit for Depo-Provera brain tumors is progressing quickly, with the MDL judge ironing out which defendants will remain named in the lawsuit and which are dismissed.

The MDL judge is implementing strict deadlines for defendants and has ruled that early depositions will not be necessary at this stage of the litigation.

April 22nd, 2025: Judge Presses Forward in Depo-Provera MDL as Generic Makers Face Scrutiny

The Depo-Provera Lawsuit is ongoing. 

The Depo-Provera brain tumor multidistrict litigation (MDL) is progressing, with U.S. District Judge M. Casey Rodgers issuing decisive rulings aimed at maintaining efficiency and transparency.

In recent weeks, the judge accepted affidavits from generic drug manufacturers Greenstone, Viatris, and Prasco, addressing their alleged involvement with the birth control shot linked to brain tumors such as meningiomas.

Prasco submitted its affidavit on time, while Greenstone and Viatris initially failed to comply—prompting an Order to Show Cause.

However, the court has since confirmed receipt of all affidavits and ruled that early depositions will not be necessary at this stage.

This streamlines the discovery process without waiving plaintiffs’ rights to challenge the generics’ role later in litigation.

Plaintiffs’ attorneys are close to reaching a stipulation that may result in Prasco’s dismissal from the MDL.

Greenstone and Viatris, however, remain active defendants and are expected to fully comply with upcoming discovery obligations regarding product distribution and liability.

Judge Rodgers’ active case management has ensured steady progress in a rapidly growing MDL, which now includes thousands of women alleging they developed brain tumors after receiving Depo-Provera injections.

The court’s insistence on strict deadlines sends a strong message that delays and noncompliance will not be tolerated.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The federal judge overseeing all Depo-Provera brain tumor lawsuits has scheduled monthly case management conferences through 2025, aimed at keeping the litigation on track for early bellwether trials.

These lawsuits, centralized in a multidistrict litigation (MDL) before U.S. District Judge M. Casey Rodgers in the Northern District of Florida, involve claims that Pfizer and other manufacturers failed to warn about the risk of meningioma brain tumors linked to long-term use of the birth control injection.

As of now, at least 130 cases have been filed, though that number is expected to grow significantly.

In a proactive move, Judge Rodgers independently selected five pilot cases for early trials and is pushing both sides to make consistent progress.

The next status conference is scheduled for May 30.

While early trials may not begin until late 2026 or early 2027, their outcomes are expected to shape future settlement negotiations and influence the direction of thousands of similar claims.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Lawsuit is ongoing. 

U.S. District Judge M. Casey Rodgers is holding parties accountable in the Depo-Provera brain tumor MDL, recently issuing an order to Show Cause after generic manufacturers Greenstone and Viatris missed a court deadline.

The defendants were given fourteen days under Case Management order No. 2 to submit the documentation to file a Notice of Compliance.

While Prasco met the deadline, Greenstone and Viatris did not.

This type of court order, which demands an explanation for failure to follow judicial instructions, can carry serious consequences.

Although both later submitted required affidavits confirming non-involvement with the drug, the judge warned that future delays will not be tolerated.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Lawsuit is ongoing. 

A recent court order in the Depo-Provera multidistrict litigation (MDL) has established a formal procedure for plaintiffs to verify their medication use.

According to this ruling, plaintiffs must submit a “Plaintiff Proof of Use/Injury Questionnaire” within 120 days of March 14, 2025, or within 120 days of filing for newly added cases.

To aid in this process, the court has approved a method for obtaining third-party records to confirm whether individuals received Depo-Provera or its generic alternative, DMPA.

Since many plaintiffs may have received the injection years ago, accessing conventional medical records can be challenging.

The court order requires that third-party organizations, including pharmacies, healthcare providers, insurers, and military medical institutions, produce documents that may assist in verifying usage.

This documentation could include purchase histories, shipping logs, or insurance payment data that indicate a facility’s administration of Depo-Provera or a similar medication.

To simplify the retrieval of these records, the court has authorized plaintiffs to use a standardized HIPAA and HITECH-compliant release form and a medical provider identification form.

If a provider does not voluntarily comply with a request, plaintiffs’ legal teams can issue subpoenas without encountering additional procedural barriers.

Additionally, the order mandates that third-party entities comply with these subpoenas or requests without imposing unnecessary administrative burdens.

Restrictions such as proprietary forms, original signatures, or excessive processing fees that might obstruct access to records are prohibited.

This court directive represents a significant advancement in enabling plaintiffs to obtain crucial documentation to support their cases.

By offering a structured and enforceable method, it seeks to reduce challenges related to incomplete or inaccessible medical records, thus enhancing efficiency in the litigation process.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

A recent court order in the Depo-Provera multidistrict litigation (MDL) has established a formal procedure for plaintiffs to verify their medication use.

According to this ruling, plaintiffs must submit a “Plaintiff Proof of Use/Injury Questionnaire” within 120 days of March 14, 2025, or within 120 days of filing for newly added cases.

To aid in this process, the court has approved a method for obtaining third-party records to confirm whether individuals received Depo-Provera or its generic alternative, DMPA.

Since many plaintiffs may have received the injection years ago, accessing conventional medical records can be challenging.

The court order requires that third-party organizations, including pharmacies, healthcare providers, insurers, and military medical institutions, produce documents that may assist in verifying usage.

This documentation could include purchase histories, shipping logs, or insurance payment data that indicate a facility’s administration of Depo-Provera or a similar medication.

To simplify the retrieval of these records, the court has authorized plaintiffs to use a standardized HIPAA and HITECH-compliant release form and a medical provider identification form.

If a provider does not voluntarily comply with a request, plaintiffs’ legal teams can issue subpoenas without encountering additional procedural barriers.

Additionally, the order mandates that third-party entities comply with these subpoenas or requests without imposing unnecessary administrative burdens.

Restrictions such as proprietary forms, original signatures, or excessive processing fees that might obstruct access to records are prohibited.

This court directive represents a significant advancement in enabling plaintiffs to obtain crucial documentation to support their cases.

By offering a structured and enforceable method, it seeks to reduce challenges related to incomplete or inaccessible medical records, thus enhancing efficiency in the litigation process.

Additionally, the Depo-Provera Lawsuit experienced a significant increase in new filings between March and April 2025.

Between February and March, the litigation saw 78 new cases filed.

By April 1st, the number of Depo-Provera Lawsuits pending surged to 130, an increase of 52 new cases.

This notable rise in filings reflects growing attention to the potential risks associated with Depo-Provera, particularly in relation to claims of brain tumor risk linked to its use.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

March 18th, 2025: Depo-Provera Lawsuits Move Forward with Direct Filing in MDL

The Depo-Provera Lawsuit is ongoing. 

The U.S. District Judge overseeing Depo-Provera brain tumor lawsuits has authorized direct filing in the multidistrict litigation (MDL), streamlining the process as more women file claims against the birth control shot’s manufacturer.

Judge M. Casey Rodgers, presiding in the Northern District of Florida, issued a case management order allowing plaintiffs to file directly in the MDL, avoiding delays from transferring cases between courts.

The litigation centers on allegations that Depo-Provera increases the risk of meningioma, a type of benign brain tumor, and that manufacturers failed to warn women and doctors.

Unlike typical mass tort cases, the MDL will not require a master complaint, short-form complaints, or a Science Day, as the court deemed them unnecessary.

Judge Rodgers has also appointed 63 attorneys to leadership roles, including those overseeing discovery, expert testimony, and trial preparation.

The litigation is expected to grow rapidly, with five pilot cases selected for early bellwether trials.

The MDL webpage is now live for case updates, and the next status conference date is pending.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Multidistrict Litigation (MDL) is Progressing. 

The Depo-Provera multidistrict litigation (MDL) is progressing under Judge Rodgers, with both sides finalizing a structured case management plan.

Plaintiffs can now file cases directly into the MDL, expediting the process by which individuals can file Depo-Provera Lawsuits.

A pilot case schedule is in place, setting deadlines for amended complaints, discovery, expert disclosures, and dispositive motions.

A central dispute remains: whether expert testimony is necessary on preemption.

Plaintiffs argue it is, while Defendants seek early dismissal based on legal grounds.

Key agreements include confidentiality protections, proof of Depo-Provera use and injury, and Pfizer’s document production requirements.

Plaintiffs secured 35 deposition days for Pfizer witnesses, plus additional time for other Defendants, with remote and video depositions permitted.

Generic distributors Greenstone and Prasco may be dismissed in cases where Plaintiffs didn’t use their products.

Special Master David Herndon and CPA Randall Sansom will oversee case management and attorney compensation.

Both sides agreed that a Science Day is unnecessary for now, keeping medical monitoring class actions on hold.

Discovery is now underway, and more developments are expected in the coming months.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Lawsuit is ongoing. 

A new case report warns that Depo-Provera birth control shots may increase the risk of severe blood clots, following a 21-year-old woman’s multiple pulmonary embolisms shortly after receiving the injection.

Doctors at Cape Fear Valley Medical Center documented the case in the journal Cureus, describing how the patient developed phlegmasia cerulea dolens (PCD), a rare and life-threatening form of deep vein thrombosis (DVT).

She required extensive medical intervention, including thrombectomy and anticoagulation therapy.

This follows a recent JAMA study linking Depo-Provera to the highest risk of serious blood clots among hormonal contraceptives.

Meanwhile, Depo-Provera Lawsuits over brain tumors are rapidly increasing, with about 70 cases consolidated in multidistrict litigation (MDL) in Florida.

More claims are expected as women diagnosed with intracranial meningiomas connect their condition to the long-term use of the contraceptive.

The court is preparing for bellwether trials to help determine how juries will respond to evidence.

If settlements are not reached, each case may proceed to trial individually.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The U.S. District Judge overseeing the federal Depo-Provera Lawsuit, Judge Casey Rodgers, has called for female attorneys to apply for leadership roles within the multidistrict litigation (MDL).

The MDL was established after studies linked Depo-Provera, a popular birth control shot, to an increased risk of brain tumors, particularly meningiomas.

Given that all plaintiffs in the case are women, Judge Rodgers emphasized the need for adequate female representation in the leadership team.

She stated that while not every position must be filled by a female attorney, it is important that women are properly represented.

The deadline for attorney applications is March 7, 2025, with selected lawyers responsible for handling discovery, managing evidence, and advocating on behalf of all plaintiffs in the MDL.

These cases will not be binding for others in the litigation but are expected to influence settlement discussions, as they will provide valuable insights into how juries may respond to similar claims in the future.

This call for female leadership comes amid backlash from a conservative judicial group, the “Article III Project,” which filed a complaint accusing Judge Rodgers of putting gender above merit.

Despite the complaint, Depo-Provera injury lawyers have strongly criticized the group’s actions, affirming that the focus on gender diversity is crucial to ensure fair representation of the plaintiff group, which consists entirely of women or their families.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Lawsuit is ongoing. 

The first status conference in the Depo-Provera multidistrict litigation (MDL) is scheduled for Friday, February 21.

A status conference is an initial court meeting where the judge, attorneys, and involved parties discuss case management, procedural timelines, and next steps.

This allows the court to establish deadlines, address preliminary legal issues, and coordinate discovery efforts before moving forward with litigation.

As the case progresses, this conference will help determine the pace and structure of the lawsuits filed against Depo-Provera’s manufacturers.

More updates to follow as proceedings continue.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Depo Provera MDL Assigned to Judge Rodgers

The Depo Provera MDL has been officially formed and assigned to Judge Rodgers in the Northern District of Florida.

This decision came as a surprise, as plaintiffs sought California and defendants preferred New York, but the JPML panel ultimately selected the Northern District of Florida, citing Judge Rodgers’ mass tort experience.

Judge Rodgers is well known for overseeing the 3M earplug litigation, and with that case winding down, she now takes on another high-profile mass tort that could span the next five years.

While plaintiffs didn’t get their preferred venue, they are optimistic about Rodgers’ ability to efficiently move the litigation toward bellwether trials and resolution.

This decision marks a turning point in the Depo-Provera litigation.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Judicial Panel on Multidistrict Litigation (JPML) held a hearing in Miami, Florida, on January 30, 2025, to discuss consolidating the Depo-Provera cases into a multidistrict litigation (MDL).

While the panel agreed to create an MDL, there was no decision on where to centralize the cases.

At the hearing, the plaintiffs’ attorneys argued that California is the best location, noting that most Depo-Provera lawsuits are already filed there.

They also pointed out that California law allows lawsuits against brand-name drug manufacturers, even when plaintiffs take a generic drug version.

Many of the affected women have undergone brain surgery and could have difficulty traveling, making California a more accessible choice if the case were to go to trial.

Pfizer, the manufacturer of Depo-Provera, wants the litigation to be based in New York, where the company is headquartered.

The company argues that key witnesses and evidence exist and that the lawsuits are spread across multiple states, not just California.

A ruling is expected in the coming weeks.

Attorneys for generic drug manufacturers suggested that filing many early cases in California may have been a legal strategy to influence the location of the MDL.

Once the JPML finalizes a venue, all federal lawsuits related to Depo-Provera will be transferred to that district for pretrial proceedings.

The MDL, designed to streamline the process, promises both sides a more efficient and expedited legal journey, providing reassurance amidst the case’s complexity.

The JPML’s impending decision will be a pivotal factor in shaping the next steps for this ongoing litigation.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

JPML Consolidation Hearing Set for Jan 30 

The U.S. Judicial Panel on Multidistrict Litigation (JPML) is set to hear arguments on January 30, 2025, about consolidating federal lawsuits related to Depo-Provera into a single multidistrict litigation (MDL). 

These cases, filed against Pfizer and other manufacturers of the birth control shot, claim that the product increases the risk of developing intracranial meningiomas—potentially life-threatening brain tumors.

If approved, the MDL will centralize all current and future lawsuits before one judge to streamline pretrial processes, discovery, and potential early test trials.

Pfizer and generic drug manufacturers have acknowledged the need for an MDL, though they disagree on the appropriate venue for consolidating cases.

The MDL will allow for coordinated pretrial proceedings, but each lawsuit will remain an individual claim.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Depo Provera Class Action Filed for Medical Monitoring

Patricia Bonilla filed a new class action lawsuit in the U.S. District Court for the Western District of Pennsylvania on January 17.

The lawsuit seeks medical monitoring for women in multiple states who received at least a year of Depo-Provera injections.

Bonilla claims these women face an increased risk of developing brain tumors and should be eligible for ongoing diagnostic testing, such as MRIs and CT scans.

The suit also calls for establishing a nationwide class or state-specific subclasses to address these claims.

Introduced in 1992, Depo-Provera is used by over 70 million women in the U.S.

While Bonilla has not been diagnosed with a brain tumor, she alleges that her use of Depo-Provera over 11 years has created a need for lifelong monitoring.

This medical monitoring lawsuit is separate from the growing number of individual injury claims filed by women who have already developed meningiomas, requiring surgical intervention and facing severe health consequences.

Plaintiffs argue that drug makers withheld crucial information about the risks despite evidence suggesting a potential link between Depo-Provera and brain tumors.

As the legal battle unfolds, the central issue remains whether manufacturers knew of the risks associated with Depo-Provera and failed to provide adequate warnings, leaving thousands of women to bear the potential health and financial consequences.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The growing number of lawsuits alleging a link between Depo Provera and meningioma brain tumors is poised for consolidation under multidistrict litigation (MDL).

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has scheduled a pivotal hearing on January 30, 2025, at the Wilkie D. Ferguson, Jr. U.S. Courthouse in Miami, Florida.

This hearing will determine whether these cases will be consolidated into an MDL, a decision that could significantly shape the litigation’s trajectory.

The location of the MDL, whether in New York or California, is a pivotal factor due to the issue of Innovator’s liability, which affects the rights of the plaintiffs.

Innovator’s liability in product liability law holds a manufacturer or developer responsible for injuries caused by a product, even if it is a new or unapproved design, due to their role in creating and bringing the product to market.

The plaintiffs advocate for the cases to be consolidated in California, where innovator liability laws allow individuals who used generic versions of Depo Provera to pursue legal action against Pfizer.

Notably, 18 of the 22 original MDL motion lawsuits were filed in California.

Conversely, Pfizer is lobbying for the MDL to be located in its home state of New York, where Innovator’s liability does not apply.

Individuals who used generic versions of Depo Provera would likely be barred from participating in the lawsuits if placed in New York.

MDL is the most effective approach for handling complex pharmaceutical cases involving many plaintiffs with diverse injuries.

Unlike a class action lawsuit, MDL centralizes cases for pre-trial proceedings under one federal judge while preserving the individual nature of each claim.

This structure is particularly well-suited to the Depo Provera litigation, as injuries like meningiomas linked to high-dose progestin require individualized evaluations of damages and circumstances.

Once the MDL is established, a streamlined process will allow plaintiffs to file short-form complaints tied to a master complaint.

This will simplify the filing process for attorneys and make it easier for new plaintiffs to join the litigation.

From there, cases are expected to progress toward resolution through individual settlements or a global settlement agreement.

A global settlement plan may include the creation of a compensation fund to address claims collectively.

A settlement matrix would determine payouts, considering each plaintiff’s unique circumstances and injuries, ensuring a fair and equitable process.

This framework is designed to provide efficiency and fairness for victims seeking justice and compensation, instilling confidence as the litigation progresses.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Alongside legal efforts in the United States, Depo-Provera Lawsuits are also being pursued in Australia by women who’ve developed brain tumors after extended use of the contraceptive injection.

A growing class action lawsuit is being pursued against Pfizer, the maker of Depo-Provera, after more Australian women are coming forward with complaints of side effects from using the drug, claiming that they were not informed of the risk.

The British Medical Journal (BMJ) study found that women who used Depo-Provera for more than a year had a five-to-six-fold increased risk of developing meningiomas compared to those who did not use the drug.

This revelation has prompted legal action in several countries, including Australia, where the drug has been used for decades.

Law firms in Australia are recruiting participants for a class action lawsuit against Pfizer, claiming the pharmaceutical giant failed to adequately warn users about the serious risks of brain tumors linked to Depo-Provera.

The class action involves Australian women who received Depo-Provera prescriptions between 1992 and the present, during which time the drug was dispensed more than 3.5 million times across the country.

These women argue that their healthcare providers never informed them about the potential dangers of long-term use of the contraceptive.

Many women reported being prescribed the drug for over a decade, while the medical guidelines recommend a maximum of using the drug for two years.

Australian lawyers and legal professionals in the United States alike are investigating whether Pfizer failed to disclose these risks, leaving millions of women unaware of the potential dangers they were facing.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.